Servicio de Microbiología, Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain.
Servicio de Enfermedades Infecciosas, Hospital del Mar-IMIM, Barcelona, Spain.
J Antimicrob Chemother. 2023 Sep 5;78(9):2291-2296. doi: 10.1093/jac/dkad234.
To assess the microbiological characteristics of Escherichia coli causing healthcare-associated bacteraemia of urinary origin (HCA-BUO) in Spain (ITUBRAS-2 project), with particular focus on ESBL producers and isolates belonging to ST131 high-risk clone (HiRC). Clinical characteristics and outcomes associated with ST131 infection were investigated.
A total of 222 E. coli blood isolates were prospectively collected from patients with HCA-BUO from 12 tertiary-care hospitals in Spain (2017-19). Antimicrobial susceptibility and ESBL/carbapenemase production were determined. ST131 subtyping was performed. A subset of 115 isolates were selected for WGS to determine population structure, resistome and virulome. Clinical charts were reviewed.
ESBL-producing E. coli prevalence was 30.6% (68/222). ST131 represented 29.7% (66/222) of E. coli isolates and accounted for the majority of ESBL producers (46/68, 67.6%). The C2/H30-Rx subclone accounted for most ST131 isolates (44/66) and was associated with CTX-M-15 (37/44) and OXA-1 enzymes (27/44). Cluster C1-M27 was identified in 4/10 isolates belonging to subclade C1/H30-R1 and associated with CTX-M-27. Additionally, ST131 isolates showed a high content of other acquired resistance genes, and clade C/ST131 isolates carried characteristic QRDR mutations. They were categorized as uropathogenic E. coli and had higher aggregate virulence scores. ST131 infection was associated with more complex patients, prior use of cephalosporins and inadequate empirical treatment but was not associated with worse clinical outcomes.
ST131 HiRC is the main driver of ESBL-producing E. coli causing HCA-BUO in Spain, mainly associated with the expansion of subclade CTX-M-15-C2/H30-Rx and the emergence of CTX-M-27-C1/H30-R1 (Cluster C1-M27).
评估西班牙(ITUBRAS-2 项目)引起医源性尿路感染血源感染(HCA-BUO)的大肠埃希菌的微生物学特征,特别关注产 ESBL 菌和属于 ST131 高危克隆(HiRC)的分离株。研究了与 ST131 感染相关的临床特征和结局。
2017 年至 2019 年,从西班牙 12 家三级保健医院的 HCA-BUO 患者前瞻性收集了 222 株大肠埃希菌血培养分离株。测定了抗菌药物敏感性和 ESBL/碳青霉烯酶的产生。进行了 ST131 亚型分析。选择了 115 株分离株的亚组进行 WGS,以确定种群结构、耐药组和毒力组。回顾了临床图表。
产 ESBL 的大肠埃希菌的流行率为 30.6%(68/222)。ST131 占大肠埃希菌分离株的 29.7%(66/222),是 ESBL 产生菌的主要来源(46/68,67.6%)。C2/H30-Rx 亚克隆占大多数 ST131 分离株(44/66),并与 CTX-M-15(37/44)和 OXA-1 酶(27/44)相关。在属于亚克隆 C1/H30-R1 的 10 株分离株中鉴定出 C1-M27 簇,与 CTX-M-27 相关。此外,ST131 分离株还具有较高的其他获得性耐药基因含量,并且 clade C/ST131 分离株携带特征性 QRDR 突变。它们被归类为尿路致病性大肠埃希菌,具有更高的总毒力评分。ST131 感染与更复杂的患者、头孢菌素的先前使用和不适当的经验性治疗有关,但与临床结局恶化无关。
西班牙引起 HCA-BUO 的产 ESBL 大肠埃希菌的主要驱动因素是 ST131 HiRC,主要与 CTX-M-15-C2/H30-Rx 亚克隆的扩张和 CTX-M-27-C1/H30-R1(C1-M27 簇)的出现相关。